ONAPGO™ (APOMORPHINE HCI) PRESCRIPTION FORM FOR VA PATIENTS



Forward the completed form to the VA pharmacy. The VA pharmacy will review and fax the document to CVS Specialty at 1-844-691-1345.

1. PATIENT INFORMATION		
Patient Name:		Alternate Contact Name:
Date of Birth: Sex: Male	Female	Relationship to Patient:
Address:		
City: State: ZIP:		Alternate Contact Email:
Cell Phone: Other Phone:	Preferre	ed Patient Language: English Spanish Other:
Patient Email:	Preferre	ed Patient Contact Method: Phone Text Email
2. VA PHARMACY INFORMATION		
Name of VA Facility:		
Address:	Suite:	City: State: ZIP:
Primary Purchasing Contact Name:	_ Telephone:	Fax: Email:
Primary Clinical Contact Name:	_ Telephone:	Fax: Email:
Secondary Purchasing Contact Name:	_ Telephone:	Fax: Email:
Secondary Clinical Contact Name:	Telephone:	Fax: Email:
Payment Method: Credit Card (call pharmacy contact)	E-invoice T	Tungsten Network
Purchase Order #:		Ship to: Patient VA Pharmacy
3. PRESCRIBER INFORMATION		
Prescriber Name (First, MI, Last):		NPI #:
Facility Name:		Office Contact:
Office Phone:		Office Fax:
Address:		City: State: ZIP:
4. ONAPGO PRESCRIPTION INFORMATION		_
Confirm Diagnosis: ICD-10: G20.A2 Parkinson's disease without dyskinesia, with fluctuations	ICD-10:	G20.B2 Parkinson's disease with dyskinesia, with fluctuations Other:
FILL OUT ALL SECTIONS BELOW - A, B, C, & D		
Required for all new patients If replacement needed:		
ONAPGO Infusion Device & Kit (1)		Replacement Infusion Device & Kit (1)
Provided to patient at start, programmed by HCP and/or Circle of Care As determined by manufacturer Clinical Nurse Navigator		
B Continuous Dose Prescription Under medical supervision, infuse subcutaneously Lowest continuous dosage is 1.0 mg/hr		
Select one: 16 hours or less or hours hours		
Max recommended daily dose, including extra doses, is 98 mg Continuous dosage: 1.0 mg/hr or mg/hr (1 cartridge per day)		
Titrate continuous dosage by: 0.5 mg/hr or 1 mg/hr INSTRUCTIONS: Titrate every 1-7 days to therapeutic effect & tolerability		
None 1 extra dose 2 extra doses 3 extra doses None 1 extra dose 2 extra doses 3 extra doses		
Hold initiating/programming extra dose until continuous dosage is No more than 3 extra doses per day over 16 hours with at least 3 hours		
ontimized Ves No		
further adjustment of the continuous dosage. If extra dose selected, complete below		
Extra dose: 0.5 mg or 1 mg or <u></u>	mg	
Titrate extra dose by: 0.5 mg or 1 mg		Titrate every 1-7 days to therapeutic effect & tolerability
D Dispense Quantity: 30 Cartridges (1 cartridge per day) Refills: 11 refills or refills		
Cost of medication is not inclusive of the ONAPGO device and ancillary supplies. Supplies listed below are standard for a 30-day prescription: Thirty (30) ONAPGO cartridge holders One (1) gallon sharps container Four (4) boxes of Infusion Sets [proximal female luer lock connector, line 42" or less, 90-degree cannula insertion angle, and subcutaneous needle with no more than 9 mm insertion depth] Two hundred (200) alcohol swabs.		
Titration Orders: Continuous and extra dose titration procedures, per full Prescribing Information, under medical supervision. Titrate by dose increments prescribed above, as directed by prescriber, at start, every few days and as needed per patient response until patient reaches therapeutic effect or max continuous dosage of 6 mg/hr or 98 mg/day.		
Prescriber Signature and Date — No Stamps OR		
Dispense As Written / Brand Medically Necessary / Do Not Substitute / No Substitution / DAW / May Not Substitute	Date:	May Substitute / Product Selection Permitted / Date: Substitution Permissible
IMPORTANT: If complementary in-home Start and Titration support/education by the Supernus® Circle of Care™ Clinical Nurse Navigator is requested by the patient, a copy of this prescription form must also be faxed to the Supernus HUB at 1-888-525-2431.		
I certify that the information in this ONAPGO Prescription Form is accurate to the best of my knowledge and that I prescribed ONAPGO based on medical necessity. I confirm that I obtained my patient's authorization, in compliance with applicable laws, to share their health information with Supernus Pharmaceuticals and the Circle of Care™ program for education		

Supernus® Pharmaceuticals

and support. I agree to provide additional information if requested and authorize the program to transmit the prescription to the pharmacy.